According to the American Migraine Foundation, over 39 million Americans suffer from migraines, a neurological disorder that may be crippling and devastating. While exact cause of migraines is not fully understood, but it is believed to involve a combination of genetic, environmental, and neurochemical factors. Despite the challenges in managing migraine pain, ketamine infusion therapy has demonstrated significant efficacy.
Ketamine is known to modulate NMDA receptor and the release of glutamate, which help to block pain signals and to dampen the transmission of pain signals. As an anesthetic used for pain relief, ketamine also has anti-inflammatory properties that helps to alleviate migraine attacks. Currently, ketamine therapy, under medical supervision, is being explored as a potential treatment option for individuals who experience severe and refractory migraines that have not responded to other standard treatments.